Current and future management options for myelodysplastic syndromes

Drugs

Volumn 70, Issue 11, 2010, Pages 1381-1394

  Bryan, Jeffrey ^a   Jabbour, Elias ^a   Prescott, Hillary ^a   Garcia Manero, Guillermo ^a   Issa, Jean Pierre ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antithymocyte globulin, therapeutic use; Azacitidine, therapeutic use; Clofarabine, therapeutic use; Darbepoetin alfa, therapeutic use; Decitabine, therapeutic use; Deferasirox, therapeutic use; Deferoxamine, therapeutic use; Erythropoietins, therapeutic use; Farnesyl transferase inhibitors, therapeutic use; Granulocyte colony stimulating factors, therapeutic use; Histone deacetylase inhibitors, therapeutic use; Lenalidomide, therapeutic use; Myelodysplastic syndromes, treatment; Research and development; Romiplostim, therapeutic use

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CLOFARABINE; CORTICOSTEROID; CYCLOSPORIN A; CYTARABINE; DEFERASIROX; DEFEROXAMINE; ENTINOSTAT; EZATIOSTAT; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; LENALIDOMIDE; LONAFARNIB; MOCETINOSTAT; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PANOBINOSTAT; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; ROMIPLOSTIM; THYMOCYTE ANTIBODY; TIPIFARNIB; TLK 199; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ADENINE NUCLEOTIDE; ARABINONUCLEOSIDE; BENZAMIDE DERIVATIVE; FARNESYL TRANS TRANSFERASE; FC RECEPTOR; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; IRON CHELATING AGENT; NEW DRUG; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; THALIDOMIDE; THROMBOPOIETIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIMICROBIAL THERAPY; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FERRITIN BLOOD LEVEL; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENE TRANSLOCATION; HEMOSIDEROSIS; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE ERYTHEMA; IRON CHELATION; IRON OVERLOAD; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; TERATOGENICITY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE MARROW; DNA METHYLATION; DRUG EFFECTS; MYELODYSPLASTIC SYNDROMES; PATHOPHYSIOLOGY; RISK FACTOR;

ADENINE NUCLEOTIDES; ANEMIA; ARABINONUCLEOSIDES; BENZAMIDES; BONE MARROW; DNA METHYLATION; DRUGS, INVESTIGATIONAL; FARNESYLTRANSTRANSFERASE; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IRON CHELATING AGENTS; MYELODYSPLASTIC SYNDROMES; PIPERAZINES; PYRIMIDINES; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; RISK FACTORS; THALIDOMIDE; THROMBOPOIETIN;

EID: 77954555064     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11537920-000000000-00000     Document Type: Review

References (92)

1. Faderl S, Kantarjian H. Myelodysplastic syndromes. In: DeVita V, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2005: 2144-2154
2. Faderl S, Kantarjian H. Novel therapies for myelodysplastic syndromes. Cancer 2004 Jul 15; 101 (2): 226-241
3. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haemato-logica 1998 Jan; 83 (1): 71-86
4. Estey E. Acute myeloid leukemia and myelodysplastic syn-dromes in older patients. J Clin Oncol 2007 May; 25 (14): 1908-1915 (Pubitemid 46854425)
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982 Jun; 51 (2): 189-199
6. Harris NJ, Jaffe ES, Diebold J, et al. World Health Orga-nization lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1977. J Clin Oncol 1999 Dec; 17 (12): 3835-3849
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [published erratum appears in Blood 1998 Feb 1; 91 (3): 1100]. Blood 1997 Mar 15; 89 (6): 2079-2088
8. Haase D, Estey E, Steidl C, et al. Multivariate evaluation of the prognostic and therapeutic relevance of cytogenetics in a merged European-American cohort of 3860 patients with MDS [abstract no. 247]. Blood 2007 Nov 16; 110 (11): 247
9. Strom SS, Velez-Bravo V, Estey EH. Epidemiology of myelodysplastic syndromes. Semin Hematol 2008 Jan 1; 45 (1): 8-13
10. Malcovati L, Germing U, KuendgenA, etal. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007 Aug 10; 25 (23): 3503-3510
11. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008 Sep 15; 113 (6): 1351-1361
12. Kantarjian H, O'Brien S, Cortes J, et al. Therapeutic ad-vances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 2008 Oct 1; 113 (7 Suppl.): 1933-1952
13. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999 Dec 23; 341 (26): 1986-1995
14. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematology 2008 Nov; 83 (11): 858-861
15. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989 Jul 1; 2 (8653): 27-30
16. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994 Sep 1; 331 (9): 567-573
17. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci 1998 Jun 30; 850: 191-201
18. Shalitin S, Carmi D, Weintrob N, et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005 Feb; 74 (2): 93-100
19. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract no. 640]. Blood 2008 Nov 16; 112 (11): 640
20. Cazzola M, Malcovati L. Myelodysplastic syndromes: coping with ineffective hematopoiesis. N Engl J Med 2005 Feb 10; 352 (6): 536-538
21. Malcovati L, Della Porta M, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision-making. J Clin Oncol 2005 Oct; 23 (30): 7594-7603
22. Exjade (deferasirox) [prescribing information]. Novartis Pharmaceuticals Corporation, 2007 [online]. Available from URL: http://www.pharma.us.novartis. com/product/pi/pdf/exjade.pdf [Accessed 2010 Apr 10]
23. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008 Feb; 80 (2): 168-176
24. Gattermann N, Schmid M, Della Porta M, et al. Efficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial [abstract no. 633]. Blood 2008 Nov 16; 112 (11): 633
25. Cappellini MD, Vichinsky E, Galanello R, et al. Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias [abstract no. 2777]. Blood 2007 Nov 16; 110 (11): 2777
26. Alessandrino EP, Amadori S, Barosi G, et al. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes: a statement from the Italian Society of Hematology. Haematologica 2002 Dec; 87 (12): 1286-1306
27. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003 Jan; 120 (2): 187-200
28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myelodysplastic syndromes. V.1.2009 [online]. Available from URL: http://www.nccn. org/professionals/physician-gls/pdf/mds.pdf [Accessed 2009 May 23]
29. The Nordic MDS Group Care Program. Guidelines for the diagnosis and treatment of the myelodysplastic syndromes [online]. Available from URL: http://www.nmds.org/ez4/index.php?/nmds/Nordic-Care-Programme [Accessed 2010 Jun 14]
30. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. J Clin Oncol 2008 Jan; 26 (1): 132-149
31. Stein RS, Abels RI, Krantz SB. Pharmacologic doses of re-combinant human erythropoietin in the treatment of myelo-dysplastic syndromes. Blood 1991 Oct 1; 78 (7): 1658-1663
32. Italian Cooperative Study Group for rHuEpo in Myelodys-plastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes: Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998 Dec; 103 (4): 1070-1074
33. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995 Jan; 89 (1): 67-71
34. Mannone L, Gardin C, Quarre MC, et al. High-dose dar-bepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome: results of a phase II study. Br J Haematol 2006 Jun; 133 (5): 513-519
35. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelo-dysplastic syndromes. Br J Haematol 2005 Jan; 128 (2): 204-209
36. Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low-and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005 Dec; 16 (12): 1921-1927
37. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000 Dec 1; 96 (12): 3671-3674
38. Moyo V, Lefebvre P, Duh MS, et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelo-dysplastic syndromes: a meta-analysis. Ann Hematol 2008 Jul; 87 (7): 527-536
39. Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than ery-thropoietin alone to treat anemia in low-risk myelodys-plastic syndromes: results from a randomized single-centre study. Ann Hematol 2006 Mar; 85 (3): 174-180
40. Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulo-cyte colony-stimulating factor for the treatment of myelo-dysplastic syndromes: a randomized, controlled trial. Blood 2004 Jul 15; 104 (2): 321-327
41. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008 Jul 20; 26 (21): 3607-3613
42. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997 Nov; 99 (2): 344-351
43. Rose EH, Abels RI, Nelson RA, et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995 Apr; 89 (4): 831-837
44. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelo-dysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003 Mar; 120 (6): 1037-1046
45. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelo-dysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009 Jun 29; 114 (12): 2393-2400
46. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003 Oct 15; 102 (8): 3025-3027
47. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002 Sep 1; 100 (5): 1570-1574
48. Wang H, Chuhjo T, Yasue S, et al. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. Blood 2002 Dec 1; 100 (12): 3897-3902
49. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008 Jan; 45 (1): 39-48
50. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002 Aug 6; 137 (3): 156-163
51. Stadler M, Germing U, Kliche K-O, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymoycte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004 Mar; 18 (3): 460-465
52. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloprolifera-tive diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002 Aug 15; 347 (7): 481-487
53. Magnusson MK, Meade KE, Nakamura R, et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor b receptor fusion oncogene. Blood 2002 Aug 1; 100 (3): 1088-1091
54. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001 Aug 15; 98 (4): 958-965
55. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005 Feb 10; 352 (6): 549-557
56. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 Oct 5; 355 (14): 1456-1465
57. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyo-types other than deletion 5q. Blood 2008 Jan 1; 111 (1): 86-93
58. Garcia-Manero G. Modifying the epigenome as a ther-apeutic strategy in myelodysplasia. Hematology Am Soc Hematol Educ Program 2007: 405-411
59. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993 May; 7 Suppl. 1: 21-29
60. Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921 [abstract no. 46]. Ann Hematol 1994; 68: A12
61. Silverman LR, Demakos EP, Peterson BL, et al. Random-ized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002 May 15; 20 (10): 2429-2440
62. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelo-dysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006 Aug 20; 24 (24): 3895-3903
63. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009 Mar; 10 (3): 223-232
64. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine im-proves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006 Apr 15; 106 (8): 1794-1803
65. WijerMans P, Suciu S, Baila L, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups [abstract no. 226]. Blood 2008 Nov 16; 112 (11): 226
66. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelo-monocytic leukemia. Blood 2007 Jan 1; 109 (1): 52-57
67. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the Interna-tional Working Group (IWG) response criteria in myelo-dysplasia. Blood 2006 Jul 15; 108 (2): 419-425
68. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the Alternative Dosing for OutPatient Treatment (ADOPT) trial. J Clin Oncol 2009 Aug 10; 27 (23): 3842-3848
69. Kantarjian HM, O'Brien S, Huang X, et al. Survival ad-vantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007 Mar 15; 109: 1133-1137
70. Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother 2007 Jan; 8 (1): 65-73 (Pubitemid 46070830)
71. Silverman LR, Fenaux P, Mufti GJ, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (pts) with myelodysplastic syndromes (MDS) [abstract no. 227]. Blood 2008 Nov 16; 112 (11): 227
72. Garcia-Manero G, Couriel DR, Tambaro PF, et al. A phase II randomized bayesian study of very low dose subcutaneous decitabine administered daily or weekly times three in patients with lower risk myelodysplastic syndrome (MDS) [abstract no. 119]. Blood 2009 Nov 20; 114 (22): 119
73. Escalation study to determine bioavailability of a single oral dose of decitabine in patients with myelodysplastic syndrome (MDS) [ClinicalTrials.gov identifier NCT00941109]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jun 14]
74. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic re-sponse to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009 Apr 10; 27 (11): 1850-1856
75. Martin MG, Walgren RA, Procknow E, et al. A phase II study of 5-day intravenous azacitidine in patients with myelodys-plastic syndromes. Am J Hematol 2009 Sep; 84 (9): 560-564
76. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004 Sep 1; 104 (5): 1266-1269
77. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplstic syndrome. Blood 2007 Oct 1; 110 (7): 2302-2308
78. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia. Blood 2006 Nov 15; 108 (10): 3271-3279
79. Faderl S, Garcia-Manero G, Ravandi F, et al. Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelo-dysplastic syndrome (MDS) [abstract no. 222]. Blood 2008 Nov 16; 112 (11): 222
80. A dose confirmation study of oral clofarabine for previously treated adult patients with intermediate-2 or high risk myelodysplastic syndromes (MDS) [ClinicalTrials.gov identifier NCT00531232]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jun 14]
81. Safety and tolerability of oral clofarabine in intermediate to high risk myelodysplastic patients [ClinicalTrials.gov identifier NCT01003678]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jun 14]
82. Oral clofarabine study in patients with myelodysplastic syndrome [ClinicalTrials.gov identifier NCT00299156]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jun 14]
83. Clofarabine in high risk myelodysplastic syndrome (MDS) [ClinicalTrials.gov identifier NCT01063257]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jun 14]
84. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyl-transferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003 Dec 15; 102 (13): 4527-4534
85. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodys-plastic syndrome. J Clin Oncol 2004 Apr 1; 22 (7): 1287-1292
86. Fenaux P, Raza A, Mufti GJ, et al. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood 2007 May 15; 109 (10): 4158-4163
87. Feldman EJ, Cortes J, DeAngelo DJ, et al. On the use of lo-nafarnib in myelodysplastic syndrome and chronic myelo-monocytic leukemia. Leukemia 2008 Sep; 22 (9): 1707-1711
88. Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [abstract no. 250]. Blood 2007 Nov 16; 110 (11): 250
89. Kantarjian H, Giles F, Greenberg P, et al. Effect of romi-plostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine [abstract no. 224]. Blood 2008 Nov 16; 112 (11): 224
90. Fenaux P, Kantarjian H, Lyons R, et al. An open-label ex-tension study evaluating the long-term safety and efficacy of romiplostim in thrombocytopenic patients (pts) with myelodysplastic syndromes (MDS) [abstract no. 2765]. Blood 2009 Nov 20; 114 (22): 2765
91. Greenberg PL, Garcia-Manero G, Moore MR, et al. Efficacy and safety of romiplostim in patients with low or intermediate-risk myelodysplastic syndrome (MDS) receiving decitabine [abstract no. 1769]. Blood 2009 Nov 20; 114 (22): 1769
92. Lyons RM, Larson RA, Kosmo MA, et al. Randomized phase II study evaluating the efficacy and safety of romi-plostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide [abstract no. 1770]. Blood 2009 Nov 20; 114 (22): 1770